Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Scientists create new method to make peptide stapling widely available

UK scientists have created a new method to structure peptides, which they say will be cheaper and make the process of using stapled peptides in drug discovery much more widely available. The method developed by the nine-strong University of Leeds team, and exp

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

UK scientists have created a new method to structure peptides, which they say will be cheaper and make the process of using stapled peptides in drug discovery much more widely available.

The method developed by the nine-strong University of Leeds team, and exploiting synthetic chemistry developed at University College London, is more versatile, cheaper, completely reversible and results in peptides whose pharmacokinetic properties, such as solubility could be easily tuned, according to Professor Andrew Wilson, who led the study.

The approach could allow skilled scientists to constrain a peptide, deliver it to a particular cell and then unconstrain it, preventing it from leaving the cell again.

Making peptides more useful

Scientists and drug manufacturers generally regard peptides with skepticism, believing they are too unreliable to be used as drugs because they are easily degraded in cells and are difficult to manipulate.

However, research initiated at Harvard University found a method to introduce a brace which could be attached to a peptide, strengthening its active structure and making it more stable and less likely to degrade.

This process, known as 'stapling' uses a specific synthetic method and has now become a recognized approach in peptide drug discovery, even resulting in new start-up companies. Stapled peptides do not break down, bind better to proteins and have improved pharmacokinetic properties such as cell uptake.

Protein-protein interactions

A widespread change in perspective on peptides has arisen due to the need for the pharmaceutical industry to develop drugs that act on protein-protein interactions, in contrast to the traditional 'lock-and-key' mode of recognition exploited by most current drugs. Small molecules that act on protein-protein interactions must cover a larger less convex surface.

Professor Wilson, whose team works on this problem, said "Scientists have had limited success in developing traditional small molecules that act on protein-protein interactions, and developing peptides in this way is an attractive alternative."

He added: "The much greater levels of contact between the peptide and protein can be exploited to achieve higher affinity and selectivity, so we have become excited by this alternative approach to stapling."

Naturally-occurring amino acids

The University of Leeds team has taken the principle of peptide stapling to a new level. The method is based on the reaction of two thiols in a peptide sequence with a dibromomaleimide reagent.

When the two thiols are correctly placed in the peptide sequence the reaction results in the structure becoming locked in a specific and bioactive helical shape which is more stable.

The method works on peptide sequences containing the natural and common amino acids cysteine or homocysteine. This will permit access to suitable peptides via routine chemical and biological methods.

Professor Wilson, from the University of Leeds' School of Chemistry and Astbury Centre for Structural Molecular Biology said: "Our approach to protein stapling is more flexible, potentially cheaper, and should be easier to use in chemical biology and drug discovery.

The full research paper Double Quick, Double Click Reversible Peptide 'Stapling' is published in the Royal Society of Chemistry's Chemical Science journal on 31 May 2017.

Dr. Michael Webb, Associate Professor of Organic Chemistry at the University of Leeds, said: "We've developed a new method to rapidly introduce a functional constraint into two model peptides which enhances a range of biophysical and biochemical properties. Unlike other methods, it can also be reversed.

"This approach can be carried out using naturally available amino acids, potentially bringing peptide stapling to a larger community.

"The ability to reverse the constraint may enable delivery of peptide-based reagents into cell where they can be unconstrained and be less easy to transport back out again."

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
02How does Protein A affect humans?

S. aureus is a Gram-positive and cocci-shaped bacterium, meaning that it appears purple with ‘Gram stain’, and these bacterial are seen as clusters of small, spherical cells. S. aureus is a part of the human microbiome – mostly being found on the surface of the skin and all mucous membranes (e.g. eyes, mouth and ears). They are opportunistic bacteria, meaning that if a break in the skin occurs, or if the host becomes immunodeficient in some way, S. aureus can eventually cause an infection. When S. aureus does infect a human host, it may result in a variety of different diseases, but very commonly it causes recurrent soft tissue and skin infections. These infections have become more prevalent in recent years, mainly as nosocomial forms, as methicillin-resistant strains of S. aureus (MRSA) have evolved in hospitals across the western world. In humans, protein A (once it is released into the extra-cellular environment) can bind with the ‘Fc’ fragment of immunoglobulin G (IgG) and has been observed to be antiphagocytic in vitro - which is consistent with its IgG binding abilities, as binding to IgG can interfere with bacterial attachment by the antibody. This means that it can prevent itself from being destroyed by certain elements of the human immune system (as was also similarly observed in the guinea pig experiment from 2013). S. aureus infections, such as endocarditis, are usually treated with a strong course of antibiotics. Protein A can therefore function slightly differently in different species, but always has the same goal: it interferes with the host’s B-cells within their immune system to prevent S. aureus from being phagocytosed and destroyed. This is an ideal adaptation, and when coupled with the known propensity of S. aureus to be more easily transmitted than other coagulase-positive bacteria, it indicates faster and more widespread bacterial transmission.

Source: www.news-medical.net ↗
03What are 'dancing molecules'?

Stupp and his team posited that "dancing molecules" might encourage the stubborn tissue to regenerate. Previously invented in Stupp's laboratory, dancing molecules are assemblies that form synthetic nanofibers comprising tens to hundreds of thousands of molecules with potent signals for cells. By tuning their collective motions through their chemical structure, Stupp discovered the moving molecules could rapidly find and properly engage with cellular receptors, which also are in constant motion and extremely crowded on cell membranes. Once inside the body, the nanofibers mimic the extracellular matrix of the surrounding tissue. By matching the matrix's structure, mimicking the motion of biological molecules and incorporating bioactive signals for the receptors, the synthetic materials are able to communicate with cells. "Cellular receptors constantly move around," Stupp said. "By making our molecules move, 'dance' or even leap temporarily out of these structures, known as supramolecular polymers, they are able to connect more effectively with receptors."

Source: www.news-medical.net ↗
04How long does it take for vitamins to work?

Biologically, vitamins are absorbed within hours and have instant metabolic effects, such as antioxidants that protect cells or compounds that are building blocks for making hormones. But, many factors impact their efficiency and could keep your body from fully absorbing them. Absorption and effects depend on each individual and what combination of vitamins they take. Gender, age, digestive health, medical conditions, and diet all play a role. One helpful practice to detect deficiencies is to look for the symptoms deficiencies create. Then, look for improvement in your symptoms with supplement intake. You are unlikely to see or feel changes if you do not lack nutrients. If you are chronically tired or see signs of unhealthy nails, hair, or skin, supplements may help as these are indicators that you are lacking nutrients in your diet. If you are unsure, your doctor can order tests to check for deficiencies in your blood.

Source: www.medicinenet.com ↗
05Could you discuss any ongoing or future research projects that you are particularly excited about in the field of axon biology and sncRNAs?

Certainly. We're keenly exploring extracellular vesicles as mediums for cells to communicate. These cell made vesicles often carry microRNAs and other non-coding RNAs, presenting a unique avenue to understand how neurons modulate their environment, which is especially interesting in neurological conditions. We are exploring extracellular vesicles as these tools with which cells can communicate and transfer gene expression patterns. And we're looking at, for example, how early life brain tumours such as medulloblastoma can impact neuron development and activity and how this can affect later life pain processing and neurological conditions. This has been possible via funding from the Medical Research Foundation, which supported a big collaboration between the labs of Gareth Hathway, Beth Coyle, Vicky James, Anna Grabowska and myself in Nottingham.

Source: www.news-medical.net ↗
comparison

Comparisons

Side-by-side pages for commonly compared peptides and research compounds.

Source: peptideuniv.com
Research context

Read sources and limitations before applying a claim.

Longevity, Performance & Obesity Research

A research peptide formulation developed to investigate metabolic regulation, mitochondrial function, and nutrient-sensing pathways.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →